Pub Date : 2023-11-16DOI: 10.29011/2833-3497.000157
{"title":"Metastatic Prostate Cancers at the University Hospital Center-Bogodogo (CHU-B) in OUAGADOUGOU : Situation in a Resource-Limited Country like Burkina Faso","authors":"","doi":"10.29011/2833-3497.000157","DOIUrl":"https://doi.org/10.29011/2833-3497.000157","url":null,"abstract":"","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"286 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139268602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-28DOI: 10.29011/2833-3497.000153
Tenorio Phm, LZ Freitas, OJ Nascimento, Osvaldo José Moreira do Nascimento
Background: In recent years, the advent of immunotherapeutic drugs, particularly checkpoint inhibitors (CIs), has revolutionized the landscape of cancer treatment, offering unprecedented hope and improved outcomes for patients. Given the increasing use of these immunotherapies, in addition to the impact on patient survival and quality of life, it is necessary to better understand adverse events related to CIs. Objective: search and analyze data contained in an important pharmacovigilance database (FAERS), in order to understand the incidence of peripheral neuropathies, as an adverse event, in patients undergoing therapy with CIs in a real-world context. Methods: This observational study analyzes post-marketing pharmacovigilance data on CIs, The study focuses on adverse events within the (FAERS) database and IQVIA Analytics databases
{"title":"Peripheral Neuropathies in Checkpoint Inhibitor Therapy: An In-depth Investigation through Pharmacovigilance Data-driven Analysis","authors":"Tenorio Phm, LZ Freitas, OJ Nascimento, Osvaldo José Moreira do Nascimento","doi":"10.29011/2833-3497.000153","DOIUrl":"https://doi.org/10.29011/2833-3497.000153","url":null,"abstract":"Background: In recent years, the advent of immunotherapeutic drugs, particularly checkpoint inhibitors (CIs), has revolutionized the landscape of cancer treatment, offering unprecedented hope and improved outcomes for patients. Given the increasing use of these immunotherapies, in addition to the impact on patient survival and quality of life, it is necessary to better understand adverse events related to CIs. Objective: search and analyze data contained in an important pharmacovigilance database (FAERS), in order to understand the incidence of peripheral neuropathies, as an adverse event, in patients undergoing therapy with CIs in a real-world context. Methods: This observational study analyzes post-marketing pharmacovigilance data on CIs, The study focuses on adverse events within the (FAERS) database and IQVIA Analytics databases","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130232793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-21DOI: 10.29011/28333497.000152
Ilerhunmwuwa Nosakhare Paul, Hakobyan Narek, A. Henry, Wasifuddin Mustafa, Abowali Hesham, B. Avezbakiyev
Background: It has been a major challenge finding an effective second-line therapy with a favorable safety profile for metastatic small cell lung cancer (SCLC) in patients who failed or relapsed following first-line platinum-based chemotherapy. Lurbinectedin was approved for SCLC in patients who relapsed or failed first-line treatment. The most common adverse event associated with it was myelosuppression. Till date, no cardiotoxicity has been described with this medication in the literature.
{"title":"Possible Lurbinectedin-associated Cardiotoxicity in a Patient with Metastatic Small Cell Lung Cancer: A Case Report","authors":"Ilerhunmwuwa Nosakhare Paul, Hakobyan Narek, A. Henry, Wasifuddin Mustafa, Abowali Hesham, B. Avezbakiyev","doi":"10.29011/28333497.000152","DOIUrl":"https://doi.org/10.29011/28333497.000152","url":null,"abstract":"Background: It has been a major challenge finding an effective second-line therapy with a favorable safety profile for metastatic small cell lung cancer (SCLC) in patients who failed or relapsed following first-line platinum-based chemotherapy. Lurbinectedin was approved for SCLC in patients who relapsed or failed first-line treatment. The most common adverse event associated with it was myelosuppression. Till date, no cardiotoxicity has been described with this medication in the literature.","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124159608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-10DOI: 10.29011/2833-3497.000151
L. Olsen, Madeline Link, P. Kent
Zoledronic acid (ZA) is used to treat osteoporosis, hypercalcemia, metabolic bone disease, cancer induced bone disease, and Paget’s disease of bone. In cancer patients with bone metastasis, it can decrease pain and occasionally induce shrinkage. For primary bone tumors, such as osteosarcoma and Ewing sarcoma, zoledronic acid has been trialed as part of combination chemotherapy strategy in high-risk patients. Osteonecrosis of the jaw is a well described side effect of ZA, but osteonecrosis of other bones is very rare. We describe three patients with relapsed primary bone tumors on zoledronic acid who had presumed relapse with new bony metastasis, that was subsequently contradicted by alternative imaging and biopsy. We hypothesize that these false positive results were due to zoledronic acid inhibiting the cycle of tumor cell proliferation and bone resorption causing bony infarcts in a tumor dependent pathway that increases osteoblast activity. We hope that awareness of this rare phenomenon will encourage practitioners to prove bone metastasis in primary bone cancers by biopsy, or alternative imaging before concluding current therapy has failed.
{"title":"Zoledronic Acid-Induced Lesions Mimicking Metastasis in Patients with Bone Cancers","authors":"L. Olsen, Madeline Link, P. Kent","doi":"10.29011/2833-3497.000151","DOIUrl":"https://doi.org/10.29011/2833-3497.000151","url":null,"abstract":"Zoledronic acid (ZA) is used to treat osteoporosis, hypercalcemia, metabolic bone disease, cancer induced bone disease, and Paget’s disease of bone. In cancer patients with bone metastasis, it can decrease pain and occasionally induce shrinkage. For primary bone tumors, such as osteosarcoma and Ewing sarcoma, zoledronic acid has been trialed as part of combination chemotherapy strategy in high-risk patients. Osteonecrosis of the jaw is a well described side effect of ZA, but osteonecrosis of other bones is very rare. We describe three patients with relapsed primary bone tumors on zoledronic acid who had presumed relapse with new bony metastasis, that was subsequently contradicted by alternative imaging and biopsy. We hypothesize that these false positive results were due to zoledronic acid inhibiting the cycle of tumor cell proliferation and bone resorption causing bony infarcts in a tumor dependent pathway that increases osteoblast activity. We hope that awareness of this rare phenomenon will encourage practitioners to prove bone metastasis in primary bone cancers by biopsy, or alternative imaging before concluding current therapy has failed.","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115459797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-02DOI: 10.29011/2833-3497.000147
{"title":"Application of Frequency Modulated RF Waves for Treating Cancers and Tumors","authors":"","doi":"10.29011/2833-3497.000147","DOIUrl":"https://doi.org/10.29011/2833-3497.000147","url":null,"abstract":"","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133852176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-23DOI: 10.29011/2833-3497.000146
{"title":"Deferred Nephrectomy after a Surprising Response to Immunotherapy in Poor Risk Patients: A Case Report","authors":"","doi":"10.29011/2833-3497.000146","DOIUrl":"https://doi.org/10.29011/2833-3497.000146","url":null,"abstract":"","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132579193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-10DOI: 10.29011/2833-3497.000144
Zijun Zhao, Xiayao Diao, Qing Cao, X. Lu
Differential Expression of Necroptosis-Related
坏死相关的差异表达
{"title":"Differential Expression of Necroptosis-Related Genes with regulating lncRNA in Triple Negative Breast Cancer to Predict Prognosis and Immunotherapy Response","authors":"Zijun Zhao, Xiayao Diao, Qing Cao, X. Lu","doi":"10.29011/2833-3497.000144","DOIUrl":"https://doi.org/10.29011/2833-3497.000144","url":null,"abstract":"Differential Expression of Necroptosis-Related","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"377 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122658139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-19DOI: 10.29011/2833-3497.000142
{"title":"Potential Biomarkers in Drug-Resistant Colorectal Cancer Cells","authors":"","doi":"10.29011/2833-3497.000142","DOIUrl":"https://doi.org/10.29011/2833-3497.000142","url":null,"abstract":"","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125411226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-26DOI: 10.29011/2833-3497.000140
{"title":"What Makes a Cancer Team Successful?","authors":"","doi":"10.29011/2833-3497.000140","DOIUrl":"https://doi.org/10.29011/2833-3497.000140","url":null,"abstract":"","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130930133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-14DOI: 10.29011/amco-130.000138
{"title":"Glypican 3 (GPC 3) In Cancer Pathogenesis and Progression","authors":"","doi":"10.29011/amco-130.000138","DOIUrl":"https://doi.org/10.29011/amco-130.000138","url":null,"abstract":"","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126546531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：